141 results on '"Grabowski, Gregory"'
Search Results
2. Environmentally relevant atrazine exposure leads to increases in DNA damage and changes in morphology in the hepatopancreas of crayfish (Faxonius virilis)
3. Therapies for lysosomal storage diseases: Principles, practice, and prospects for refinements based on evolving science
4. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus
5. GOAL-GD: A smartphone application to enhance patient engagement in a real-world study of treatment switching in patients with Gaucher disease type 1
6. Gaucher disease: Basic and translational science needs for more complete therapy and management
7. COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
8. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
9. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
10. An unexpected player in Gaucher disease: The multiple roles of complement in disease development
11. Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease
12. Extracellular Lipids Accumulate in Human Carotid Arteries as Distinct Three-Dimensional Structures and Have Proinflammatory Properties
13. Tissue Localization of Glycosphingolipid Accumulation in a Gaucher Disease Mouse Brain by LC-ESI-MS/MS and High-Resolution MALDI Imaging Mass Spectrometry
14. Overview of Inflammation in Neurometabolic Diseases
15. Glucosylceramide partnership with immunological villain in Gaucher disease
16. Ten plus one challenges in diseases of the lysosomal system
17. Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues
18. Lysosomal acid lipase deficiency: Expanding differential diagnosis
19. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry
20. C5a drives glucosylceramide accumulation and tissue inflammation in Gaucher disease
21. Response to “Letter to the Editor by Drs Block and Razani”
22. Association Between Progranulin and Gaucher Disease
23. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
24. 521. Platelets Transfusion New Role as Brain Therapeutics for Acute Neuronopathic Gaucher Disease
25. Immune cells attack and neurodegeneration in Gaucher disease
26. 374. Therapeutic Effect of Platelet Transfusions for Acute Neuronopathic Gaucher Disease
27. Combination therapy (eliglustat+velaglucerase alfa) in a pediatric patient with Gaucher disease type 1 and hereditary spherocytosis
28. CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11years of therapy: Clinical, histopathologic, and biochemical findings
29. Enzyme replacement therapy corrects Lysosomal Acid Lipase Deficiency (LALD) in a mouse model of Wolman disease/cholesteryl ester storage disease
30. The LIMP-2/SCARB2 Binding Motif on Acid β-Glucosidase
31. JCL Roundtable: Enzyme replacement therapy for lipid storage disorders
32. Reversal of advanced disease in lysosomal acid lipase deficient mice: A model for lysosomal acid lipase deficiency disease
33. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
34. Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology
35. Endogenous β-glucocerebrosidase activity in Abca12epidermis elevates ceramide levels after topical lipid application but does not restore barrier function
36. How did we get here and where are we going?
37. Clinical, biochemical and histopathological effects of 11 years of enzyme therapy in Gaucher disease type III: Unexpected CNS vascular and cellular manifestations
38. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology
39. Gaucher disease: glucosylceramide-mediated TLR4-MyD88 induction causes enhanced CXCL-13 secretion and increased B cell trafficking in a mouse model
40. Gaucher disease: Chemotactic factors and immunological cell invasion in a mouse model
41. Cell non-autonomous neuronal death implied by neuronal differentiation of induced pluripotent stem cells from Gaucher disease type 2 fibroblasts
42. Abnormal pathology findings in a patient with Gaucher disease type 3 treated with enzyme replacement therapy
43. Immunological cell type characterization and Th1–Th17 cytokine production in a mouse model of Gaucher disease
44. Is E326K glucocerebrosidase a polymorphic or pathological variant?
45. Developing Brain Imaging Markers of Treatment Response and Progression in Mucopolysaccharidosis Type II
46. Phenotypic Spectrum of Hematological and Visceral Disease in Type 3 Gaucher Disease and Response to Imiglucerase Therapy: Preliminary Analysis from the ICGG Gaucher Registry
47. A Historical Chart Review and Longitudinal Follow-Up of Identified Patients with Wolman Disease or Cholesteryl Ester Storage Disease, Lysosomal Acid Lipase Deficiency
48. Ex Vivo and in Vivo Effects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher Disease
49. Esophageal and Vertebral Artery Injuries During Complex Cervical Spine Surgery—Avoidance and Management
50. Cervical Deformity in Rheumatoid Arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.